“We evaluate personalized medicine regimes that include lab testing, a scoring system, and other factors associated with the patient,” according to Edmund Pezalla, MD, MPH.
Pezalla explained that personalized medicine is evaluated based on whether the treatments have demonstrated better outcomes or if it is clear that they will alter clinical decisions. He emphasized that just an add-on test is of no value, so diagnostics that expect clinical integration should impact outcomes.
“Companion diagnostics are enormous in this area because they help make a choice for or against a drug and using it to choose a particular pathway. [These diagnostics] measure something that can be acted on,” Pezalla said.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More